BioSpace14d
Partial Epilepsy Market Expected to Grow at a Steady CAGR of 9.8% during 2025-2035, Impelled by Escalating Prevalence of Epilepsy
Carbatrol (Carbamazepine controlled release): Shire Pharmaceuticals ... Some of these major players are GlaxoSmithKline, Novartis, UCB, Eisai, Ono Pharmaceutical, and others. These companies lead ...
BMJ18d
Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis
Her epilepsy was treatment refractory to carbamazepine despite being compliant and repeated ... Competing interests AP is a member of the steering committee for the OCTiMS study (Novartis) and ARI ...
The Boston Globe10d
Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...
MedCity News10d
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
pharmaphorum2d
A history of Novartis
Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Wall Street Journal10d
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
Novartis NOVN-2.46%decrease; red down pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The ...
FiercePharma24d
Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. The drugmaker’s first-ever Super Bowl ad is set to ...
Business Wire10d
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...
Ad Age24d
Novartis will make its Super Bowl debut with a breast cancer awareness ad
Are you a print subscriber? Activate your account. By Tim Nudd - 19 hours 17 min ago By Amir Farhang - 19 hours 17 min ago By Ashley Joseph - 1 day 17 hours ago By Ad Age Staff - 1 day 17 hours ...
STAT10d
Pharmalittle: We’re reading about AI prescribing drugs, a Novartis deal, and more
Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we ...
FiercePharma16d
TV drug ad spending reached new heights in January, as Novartis' Pluvicto toppled AbbVie's Skyrizi for top spot
According to iSpot.TV’s analysis of January TV drug ad spending data, Novartis’ prostate cancer drug Pluvicto swooped in to take the No. 1 spot on the list, with more than $47 million spent ...